RT Journal Article
SR Electronic
T1 A study protocol for an international registry observational study evaluating clinical outcomes of transcatheter versus standard surgical mitral valve operation for secondary mitral regurgitation: the TEERMISO study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.01.24316548
DO 10.1101/2024.11.01.24316548
A1 Nappi, Francesco
A1 Avtaar Singh, Sanjeet Singh
A1 Salsano, Antonio
A1 Spadaccio, Cristiano
A1 Shingu, Yasushige
A1 Wakasa, Satoru
A1 Fiore, Antonio
YR 2024
UL http://medrxiv.org/content/early/2024/11/02/2024.11.01.24316548.abstract
AB Background Secondary mitral regurgitation (SMR) is a condition affecting the left ventricle (LV) rather than the mitral valve (MV). If the mitral valve (MV) remains structurally unchanged, enlargement of the left ventricle (LV) or impairment of the papillary muscles (PM) can occur. Several mechanical interventions are available to dictate the resolution of MR. However, there is a lack of robust data to compare mitral valve replacement, mitral valve repair (including subvalvular repair), and transcatheter mitral valve procedures (TMVp). This study aims to compare the effectiveness and clinical outcomes of TMVp using the edge-to-edge mitral valve repair (TEER) technique and standard surgical mitral valve procedures (S-SMVp) in patients with SMR.Methods and analysis Five cardiac surgery centres from four European countries and Japan have collaborated to create a multicentre observational registry (TEERMISO). The registry will enrol consecutive patients who underwent mechanical intervention for SMR between January 2007 and December 2023. The investigators assessed the difference between replacement and repair for both the standard surgical approach and the transcatheter procedure. The main clinical outcome will be the degree of LV remodelling as assessed by the Left Ventricular End-Diastolic Volume Index at 10 years. The study will measure several secondary endpoints, including all-cause mortality as the primary endpoint, followed by functional status, hospitalisation, neurocognition, physiological measures (echocardiographic assessment), adverse events and reoperation.Ethics and dissemination Ethics approval was obtained in Montpellier University Hospital on 24 May 2022 (Institutional Review Board (IRB) Approval Number: IRB-MTP_2022_05_202201143). The results of the main study and each sub-analysis will be submitted for publication in a peer-reviewed journal. ClinicalTrials.gov ID: NCT05090540; IRB ID: 202201143. (Supplementary material)Strengths and limitations of this studyThis study will be conducted as a large international registry concerning interventions to correct secondary mitral regurgitation; it will provide clinicians important information about transcatheter and surgical techniques in the specific field of the secondary mitral regurgitation.The primary outcome will offer opportunity to better predict left ventricular remodeling after the procedures.The secondary outcomes of this study will offer opportunity to provide important information abut survivalThe retrospective nature of the study is a limitation to the study design.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://register.clinicaltrials.gov/prs/beta/records Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://ccn.fr/ AEadverse eventCABGcoronary artery bypass surgeryCCSCCanadian Cardiovascular Society ClassificationCHFchronic heart failureCOAPTcardiovascular Outcomes Assessment of the MitraClip Percutaneous TherapyGDMTGuideline-directed medical therapyHFheart failureICUintensive care unitLCPLeaflet and chordal proceduresLVleft ventricleLVEDPLeft ventricular end-diastolic pressureLVEFLeft Ventricular Ejection FractionMACEMajor Adverse Cardiac EventsMCGMedical College of GeorgiaMIMyocardial infarctionMVmitral valveNYHANew York Heart AssociationPCIpercutaneous coronary interventionPCWPPulmonary capillary wedge pressureRCTrandomized clinical trialsRERrespiratory exchange ratioRMARestrictive mitral annuloplastyRPErate of perceived exertionSMRSecondary mitral regurgitationS-SMVpstandard surgical mitral valve procedureTEERtranscatheter edge-to-edge mitral valve repair (TEER)TEERMISOtranscatheter Versus Standard Surgical Mitral Valve Operation for Secondary Mitral RegurgitationTMVptranscatheter mitral valve procedure